Evotec SEXSWX:EVT +4.02%68 Forward PE Ratio is 192.31 as of Jun. 29, 2026. GuruFocus rates XSWX:EVT with a GF Score™ of 68/100 and a GF Value™ of CHF6.99 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 406 Drug Manufacturers companies, Evotec SE ranks worse than 98.28% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Evotec SE Forward PE Ratio Related Terms
Evotec SE Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Evotec SE's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE Forward PE Ratio Chart
Evotec SE Annual Data
Trend
2015-12
2016-12
2018-12
2019-12
2020-12
2021-12
2022-12
Forward PE Ratio
63.29
149.25
44.05
99.01
129.87
322.58
95.24
Evotec SE Quarterly Data
2015-12
2016-03
2016-06
2016-09
2016-12
2017-03
2017-09
2018-03
2018-06
2018-12
2019-03
2019-06
2019-09
2019-12
2020-03
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
Forward PE Ratio
63.29
32.47
55.87
44.05
149.25
68.03
62.11
48.31
47.62
44.05
54.64
63.69
99.01
99.01
104.17
129.87
147.06
54.05
90.09
322.58
250.00
333.33
384.62
95.24
95.24
XSWX:EVT vs ZTS, UTHR, VTRS: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Evotec SE's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Evotec SE (XSWX:EVT) has a Forward PE Ratio of 192.31 as of Jun. 29, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Evotec SE and its competitors. According to the industry distribution chart, Evotec SE ranks #399 out of 406 companies in the Drug Manufacturers industry, placing it in the top 98.3%.
Is Evotec SE's Forward PE Ratio too high?
Evotec SE's current Forward PE Ratio is 192.31. The Drug Manufacturers industry median Forward PE Ratio is 16.98. Evotec SE's value of 192.31 is 1032.9% above this industry median. Based on the distribution chart, Evotec SE ranks #399 out of 406 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evotec SE has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Forward PE Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #399 out of 406 companies for Forward PE Ratio. This places Evotec SE in the lower half of its industry. The industry median Forward PE Ratio is 16.98. Evotec SE's value of 192.31 is 1032.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 16.98, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evotec SE's current Forward PE Ratio of 192.31 is 1032.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 16.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current Forward PE Ratio is 192.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (XSWX:EVT) is currently considered Possible Value Trap. The stock's GF Value™ is CHF6.99, compared to a current price of CHF4.50 — trading 35.6% below its estimated fair value. The current Forward PE Ratio is 192.31 and 1032.9% above the Drug Manufacturers industry median of 16.98. Evotec SE's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Evotec SE (XSWX:EVT), the current Forward PE Ratio is 192.31 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (XSWX:EVT) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of CHF4.50 is trading 35.6% below its estimated GF Value™ of CHF6.99.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for XSWX:EVT:
Forward PE Ratio: 192.31
GF Value™: CHF6.99 vs. price of CHF4.50 (35.6% below fair value)
Industry Position: 1032.9% above the Drug Manufacturers median (#399 of 406)
No single metric tells the full story. See the XSWX:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
68GF Score
Get the complete analysis for XSWX:EVT
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EVT has been successfully added to your 